MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1
M.-Y. Zhang, J. Lin, Y.-C. Kui Department of Thoracic Surgery, the Affiliated Hospital of Weifang Medical University, Weifang, China. kuiyuchuanxh@outlook.com
OBJECTIVE: To investigate the roles and the underlying mechanism of miR-345 in regulating non-small cell lung cancer (NSCLC) cell migration and invasion.
PATIENTS AND METHODS: Fifty-two pairs of NSCLC tissues and matched normal lung tissue samples were collected from NSCLC patients who had undergone surgical resection between June 2015 and August 2017 in our hospital. Human NSCLC cell lines (NCI-H460, NCI-H1299, A549 and GLC-82) and normal human bronchial epithelium cell BEAS-2B were cultured. NSCLC cell migration and invasion capacities were determined by transwell assays. The relative protein and mRNA expression level of yes-associated protein 1 (YAP1) were detected by Western blot and Quantitative Real-time polymerase chain reaction (qRT-PCR) analysis, respectively.
RESULTS: MiR-345 was prominently downregulated in NSCLC tissue specimens. Results of transwell assays showed that miR-345 overexpression could dramatically inhibit NSCLC cell migration and invasion. Additionally, data in current study also identified YAP1 as a direct functional target of miR-345 in NSCLC cells. YAP1 expressions were negatively correlated with the miR-345 expressions in NSCLC tissue samples. Moreover, YAP1 was found to be involved in the functions of miR-345 in inhibiting NSCLC cell invasion and migration.
CONCLUSIONS: All the above results indicated that miR-345 inhibited NSCLC cell migration and invasion by targeting YAP1, suggesting that miR-345/YAP1 axis might be a promising biomarker for NSCLC treatments.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
M.-Y. Zhang, J. Lin, Y.-C. Kui
MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1
Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 6
Pages: 2436-2443
DOI: 10.26355/eurrev_201903_17390